Quantcast

Latest Brain tumor Stories

2014-09-17 08:28:28

ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track LOS ANGELES, Sept. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) provides a corporate update on its plans to advance ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM), and on its portfolio of dendritic cell-based vaccines: ICT-121 for patients...

2014-09-16 08:32:04

HOUSTON, Sept. 16, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company's lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label Phase Ib study for patients with recurrent glioblastoma. "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists in the US, is pleased to announce the initiation of our randomized...

2014-09-16 08:30:30

"PIM" Designation For DCVax-L Is First Step In 2-Step Process for Early Access Approval BETHESDA, Md., Sept. 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that its DCVax-L is the first product to receive formal designation as a "Promising Innovative Medicine" (PIM) under the new "Early Access to Medicines Scheme" (EAMS) launched in the UK...

2014-09-11 12:27:08

Medical Community Members and Locals Honored For Their Tireless Support For The Cause And Ongoing Fight For A Cure WASHINGTON, Sept. 11, 2014 /PRNewswire-USNewswire/ -- Voices Against Brain Cancer is set to host its inaugural annual "Join the Voices! D.C. Walk." On Sunday, September 21, 2014 The National Mall will be filled with individuals, friends, family and loved ones joined together in support of this worthy cause. Registration begins at 8:00 AM with a 9:00 AM start time. The...

2014-09-10 16:26:43

More Than 275 Procedures Performed at Top Medical Centers Across the U.S. PLYMOUTH, Minn., Sept. 10, 2014 /PRNewswire/ -- Monteris Medical announced today that its NeuroBlate(®) System, a minimally invasive robotic laser thermotherapy tool, has now been used by leading surgeons across the U.S. in more than 275 procedures. The NeuroBlate System employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. The NeuroBlate System...

2014-09-09 08:31:48

Intraoperative neurosurgical platforms offer precision and workflow improvement for ablating brain tumors MINNEAPOLIS, Sept. 9, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that the Company's InSitu(TM) wireless coil and Monteris NeuroBlate(®) laser ablation system have been used together for the first time at a leading United States neuroscience center. This combination brought improved visualization and workflow in removing a...

2014-09-04 23:05:39

Research takes another step closer to clinical trials. Chicago, IL (PRWEB) September 04, 2014 The American Brain Tumor Association (ABTA) Discovery Grant funding of high-risk, high-impact projects continues to be a catalyst for moving innovative treatment concepts closer to the clinic. Recently, Curtana Pharmaceuticals, a privately-held, preclinical stage pharmaceutical company announced that they will continue their OLIG2 inhibitor research—research initially funded by an ABTA...

2014-09-04 08:30:32

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 4, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, will be featured as a presenting company at the SeeThruEquity Fall Microcap Investor Conference. The presentation will take place at 11AM ET on September 11, 2014 at the Convene Times Square in New York City. Jeffrey Bacha, president and CEO of DelMar, will provide an overview of DelMar's ongoing clinical development program...

2014-09-04 08:30:13

Designation of High Unmet Medical Need allows for accelerated review of regulatory submissions in Japan, the second largest medical device market in the world ST. HELIER, Jersey, Sept. 4, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that the Japanese Ministry of Health and Welfare (MHLW) has granted High Unmet Medical Need designation to the NovoTTF-100A System. This designation requires the Japanese Pharmaceutical and Medical Device Agency...

2014-09-03 23:05:54

Global research initiative to investigate long-term glioblastoma survivors. Chicago, IL (PRWEB) September 03, 2014 The American Brain Tumor Association (ABTA), in conjunction with the Brain Tumor Funder’s Collaborative (BTFC), is awarding a $2 million research grant to explore commonalities among long-term glioblastoma survivors around the world. Glioblastoma is a common and aggressive type of brain tumor most prevalent in adults ages 45-65, and affects more men than women. This highly...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related